Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma
Status:
Completed
Trial end date:
2015-01-21
Target enrollment:
Participant gender:
Summary
This clinical trial studies peripheral blood hemapoietic stem cell mobilization with the
combination of bortezomib and G-CSF (filgrastim) in multiple myeloma and non-Hodgkin lymphoma
patients.